DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C....
Category: News
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for global regulatory filings SAN DIEGO and CAMBRIDGE, England, Aug. 17, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Mundipharma today announced that the companies have completed recruitment of the pivotal Phase 3 ReSTORE trial evaluating the efficacy and safety of...
SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update
SCYNEXIS Reports Second Quarter 2021 Financial Results and Provides Corporate Update BREXAFEMME® (ibrexafungerp tablets), the first novel antifungal class drug approved by the U.S. Food and Drug Administration (FDA) in more than 20 years, qualifies for 10 years of regulatory exclusivity and has 14 years of U.S....
Iterum Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
–-Type A meeting with FDA expected late Q3 to define pathway to potential approval for Oral Sulopenem following July’s Complete Response Letter– –Cash Runway into Second Half of 2023– –Company to host conference call today at 8:30am ET– DUBLIN, Ireland and CHICAGO, Aug. 13, 2021 (GLOBE NEWSWIRE) —...
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second quarter ended June 30, 2021 and provided an update on its corporate activities and product...
Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
-Management to Host Conference Call on August 12 at 8am ET– Patient Enrollment in the ATTACK Phase 3 Registrational Trial Completed; Top-Line Data Readout Expected Early Fourth Quarter 2021 SUL-DUR Launch Planning Progresses with Appointment of Anna Diaz Triola as Chief Commercial Officer Data On SUL-DUR and ETX0462 Presented at World Microbe Forum $20 Million...
Entasis Therapeutics to Host Expert Perspectives Webinar on Acinetobacter Infections
– Virtual Event to be Held Tuesday, August 24 at 10am Eastern Time – WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that the Company will host a virtual webinar featuring presentations by Infectious...
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on August 13, 2021
DUBLIN, Ireland and CHICAGO, Aug. 06, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release...
Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO- -Cash runway substantially through Q1 2022- -Announced positive Phase 3 trial results for lefamulin in China, commercial rights assigned to Sumitomo Pharmaceuticals (Suzhou) Co., Ltd (SPC)- -Conference call today at 4:30 p.m. Eastern Time– DUBLIN, Ireland, Aug. 05, 2021 (GLOBE...
Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021
WALTHAM, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report second quarter 2021 financial results before the market opens on August 12, 2021. The company will host a conference call and...